Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Teva Parenteral Medicines, Inc.
483
•Teva Parenteral Medicines, Inc.•July 24, 2009

Teva Parenteral Medicines, Inc. – FDA 483, Jul 24, 2009

Record Details

The FDA Form 483 details numerous deficiencies at a drug manufacturing facility. The quality control unit lacks responsibility for approving/rejecting procedures impacting drug product identity, strength, quality, and purity. The company failed to submit post-approval or change-being-effected changes for a BI challenge in steam sterilization.

Several issues relate to product testing and release: - Out-of-trend bacterial endotoxin results were observed in finished product lots (e.g., MIR 09-003, MIR 09-015). - Drug product release does not include appropriate laboratory determination of conformance to final specifications. - There is no assurance that Propofol Injectable Emulsion 1% is free of bacterial endotoxin. - In-process materials are not tested for quality/purity or approved/rejected by QC. - Bioburden levels are sampled from non-sterile bulk solution and end-of-run samples (aseptically filled vials prior to sterilization). - Acceptance criteria for QC sampling/testing are inadequate to assure batches meet statistical quality control criteria.

Investigation failures include: - Unexplained discrepancies are not thoroughly reviewed, even for distributed batches. - Investigations do not extend to other batches or drug products potentially affected. - No consideration was given to other Propofol products manufactured on the same filling line.

Quality system and documentation issues: - QC unit responsibilities and procedures are not in writing.

Company
Teva Parenteral Medicines, Inc.
Inspection date
July 24, 2009
Product type
Drugs
Office
Los Angeles District Office
People
  • Binh T. Nguyen (Investigator)
  • Kham Phommachanh (Investigator)
  • Joey V. Quitania (Public Affairs Specialist)
  • Thomas J. Arista
View Company Profile

ID · 823311f0-8e08-4dd3-afe8-5e78fdadf779

Violation Codes3
21 CFR 21021 CFR 21121 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Teva Parenteral Medicines, Inc.
  • 483 - 2021-08-20August 20, 2021
  • 483 - 2019-08-30August 30, 2019
  • EIR - 2019-08-30August 30, 2019
  • 483 - 2019-01-18January 18, 2019
  • 483 - 2016-07-29July 29, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Teva Parenteral Medicines, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.